For research use only. Not for therapeutic Use.
Benzcyclane (Bencyclane; Benzcyclan) is a platelet aggregation inhibitor and a vasodilator effective in a variety of peripheral circulation disorders.
Benzcyclane, although capable of aggregating platelets by itself at very high concentrations, shows a striking inhibitory effect, over a wide range of concentrations, both on platelet aggregation induced by ADP, epinephrine or collagen and on platelet adhesiveness to glass or collagen. Clot retraction is also clearly inhibited[1]. Benzcyclane induces use-dependent inhibition of Na channels in muscle, similarly as do class 1 antiarrhytnmic drugs. Inhibition was observed with both normal and cevadine-modified Na channels[2].
| Catalog Number | I013353 |
| CAS Number | 2179-37-5 |
| Synonyms | 3-(1-benzylcycloheptyl)oxy-N,N-dimethylpropan-1-amine |
| Molecular Formula | C19H31NO |
| Purity | ≥95% |
| InChI | InChI=1S/C19H31NO/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3 |
| InChIKey | FYJJXENSONZJRG-UHFFFAOYSA-N |
| SMILES | CN(C)CCCOC1(CCCCCC1)CC2=CC=CC=C2 |
| Reference | [1]. Ponari O, et al. In vitro effects of bencyclan on coagulation, fibrinolysis and platelet function. Arzneimittelforschung. 1976;26(8):1532-8. [2]. Nánási PP, et al. Effects of bencyclane on normal and cevadine-modified Na channels in frog skeletal muscle. Gen Physiol Biophys. 1989 Oct;8(5):447-58. |
